E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hyperglyceamia during Cardiac Surgery |
|
E.1.1.1 | Medical condition in easily understood language |
High blood glucose concentration in patients undergoing cardiac surgery |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060439 |
E.1.2 | Term | Stress induced hyperglycaemia |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
the primary objective of this study is to investigate the potential of liraglutide to lower the proportion of patients needing insulin therapy during cardiac surgery when aiming for a perioperative plasma glucose of <8 mmol l-1. |
|
E.2.2 | Secondary objectives of the trial |
the secondary objectives of this study are to assess the effect of perioperative liraglutide treatment on total perioperative insulin need, glycaemic control and postoperative complications during and after cardiac surgery. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Before the first study drug treatment the sensor of a subcutaneous continuous glucose monitor is inserted into the subcutaneous tissue. This will be done in a subset of 26 patients included in the AMC or OLVG (for logistical reasons). To show a difference in % time in target range (%TIR) of 10% with a SD of 9%, a significance of 0.05, and 80% power, we need a sample size of 13 in both groups. Hence, we aim to include 26 patients in a per protocol sub-analysis. |
|
E.3 | Principal inclusion criteria |
• Adult patients, aged 18-80 years (inclusive), • No known diabetes mellitus, or • Known diabetes mellitus type 2 on oral glucose lowering medication, diet or total daily insulin dose ≤0.5 IU/kg • Scheduled for an elective cardiac surgical procedure. • Informed consent obtained before any trial-related activities are carried out. |
|
E.4 | Principal exclusion criteria |
• Diabetes mellitus type 1 • Emergency surgery • Receiving oral corticosteroid therapy • History of pancreatic surgery or acute or chronic pancreatitis • Personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia23 syndrome type 2 (MEN2) • Heart failure NYHA class IV • Serum-creatinine ≥ 133 μmol l-1 for males and ≥ 115 μmol l-1 for females, measured within 6 months before date of surgery. • Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods • Current treatment with GLP-1 analogues • Known or suspected allergy to trial products or other drugs in the same class |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The main outcome measure is the proportion of patients needing insulin therapy in the perioperative period (morning of surgery until transfer to the Intensive Care Unit) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Morning of surgery until transfer to the Intensive Care Unit |
|
E.5.2 | Secondary end point(s) |
We will assess the following secondary outcome parameters: • Total perioperative insulin use (IU/day) • Number of insulin administrations • Composite postoperative complications* • Glucose control in the perioperative period, as assessed by the mean perioperative glucose • Number of perioperative hyperglycaemic events (>11 mmol l-1) • Number of moderate perioperative hypoglycaemic events (<4 mmol l-1) • Number of severe perioperative hypoglycaemic events (<2.3 mmol l-1) • Percent of time spent in target range (4 – 8 mmol l-1) • Proportion of patients with postoperative nausea and vomiting |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Day of surgery until 30 days after surgery |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial: 30 days after surgery of the last patient included in the trial Premature study termination will be considered when the benefit to risk ratio changes during the study. This can be due to events reported in this study, but also due to events reported in other studies or regular patient care. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |